WebDoctor Encyclopedia

Lung

Thymic neuroendocrine tumours (thymic carcinoid)

Thymic neuroendocrine tumours are rare cancers of hormone-type cells in the thymus. They are different from thymoma and thymic carcinoma, behave more aggressively than carcinoids elsewhere, and can be linked to MEN1. Surgery is the main treatment.

Medically reviewed Last reviewed November 15, 2026

What are thymic neuroendocrine tumours?

Thymic neuroendocrine tumours (thymic NETs) are rare cancers of the thymus that grow from neuroendocrine cells. These are cells that behave partly like nerve cells and partly like hormone-producing gland cells. The thymus is a small organ in the front of the chest, behind the breastbone, which helps the immune system develop in early life.

The best-known thymic NETs are thymic carcinoids, which are divided into typical and atypical carcinoids. The group also includes two high-grade cancers, large cell neuroendocrine carcinoma and small cell carcinoma of the thymus. Thymic NETs make up only about 2-5% of all thymic tumours (Lausi et al., 2014).

Despite the gentle-sounding name, thymic carcinoids tend to behave more aggressively than carcinoids in other parts of the body, such as the lung or bowel (Lausi et al., 2014). They are more common in men, usually in middle age, and some are linked with an inherited condition called multiple endocrine neoplasia type 1 (MEN1).

The main treatment is surgery to remove the tumour completely. Radiotherapy, drug treatments and newer targeted therapies are used for tumours that cannot be fully removed or that have spread.

How thymic NETs differ from thymoma and thymic carcinoma

Thymic NETs are a different disease from the more common thymic tumours, thymoma and thymic carcinoma, which grow from the thymus’s epithelial cells. We describe those tumours in a separate article: Thymoma and thymic carcinoma.

Feature Thymic neuroendocrine tumours Thymoma and thymic carcinoma
Cell of origin Neuroendocrine cells Thymic epithelial cells
How common About 2-5% of thymic tumours The large majority of thymic tumours
Hormone production Can make hormones such as ACTH, causing Cushing’s syndrome Not typical
Linked immune conditions Not typical Thymoma often linked with myasthenia gravis
Inherited link MEN1 syndrome in some patients Rare
Key microscope features Neuroendocrine markers such as synaptophysin and chromogranin Epithelial and lymphocyte-rich patterns
Grading Typical carcinoid, atypical carcinoid, large cell and small cell carcinoma WHO thymoma types A, AB, B1-B3; thymic carcinoma
Special scans Somatostatin receptor PET often helpful Not usually used
Drug options Somatostatin analogues, everolimus, PRRT, chemotherapy Chemotherapy, some targeted drugs

The two groups occur in the same location and can look alike on a CT scan, so the difference is confirmed by the pathologist.

1. Key facts at a glance

Feature Details
Type of cancer Neuroendocrine neoplasm of the thymus
Where it grows Anterior mediastinum, behind the breastbone
How common Rare; 2-5% of thymic tumours
Who is affected Mainly men; median age in the 50s
Inherited link MEN1 syndrome in a minority
Hormone syndromes Cushing’s syndrome from ACTH in some patients
Main treatment Complete surgical removal
Other treatments Radiotherapy, somatostatin analogues, everolimus, PRRT, chemotherapy
Outlook About 62% alive at 5 years in a national database

2. Types

Type Grade Features Behaviour
Typical carcinoid Low Few dividing cells, no necrosis Slowest growing, but can still spread
Atypical carcinoid Intermediate More dividing cells and/or focal necrosis Frequently spreads
Large cell neuroendocrine carcinoma High Large cells, many mitoses, extensive necrosis Aggressive
Small cell carcinoma High Small cells, very high proliferation Aggressive; behaves like small cell lung cancer

Thymic carcinoids compared with carcinoids elsewhere

Feature Thymic carcinoid Lung or bowel carcinoid
Typical stage at diagnosis Often locally advanced Often localised
Carcinoid syndrome (flushing, diarrhoea) Rare More common with liver spread from bowel tumours
Cushing’s syndrome Relatively frequent Less frequent
Recurrence Common, sometimes years later Less common for typical carcinoids

3. Causes and risk factors

Risk factor Notes
Male sex Thymic NETs mainly affect men (Gaur, Leary and Yao, 2010)
Middle age Median age 57 in a national database
MEN1 syndrome Inherited condition causing parathyroid, pancreatic and pituitary tumours; thymic carcinoids occur in some, usually men

For most patients, the cause is unknown.

Thymic carcinoid and MEN1

People with MEN1 often have operations on their parathyroid glands. Guidelines have advised removing the thymus at the same time to prevent thymic carcinoid. A review of 122 patients found that this rarely detected a tumour, and some patients still developed a thymic carcinoid later. The authors concluded that careful long-term imaging surveillance may be more important (De Jong and Parameswaran, 2022).

4. How does it look

On scans

Test Typical findings
Chest X-ray Widened shadow in the middle of the chest
CT scan Mass in the anterior mediastinum, often large and sometimes invading nearby structures
MRI Helps assess invasion of vessels and heart lining
Somatostatin receptor PET (for example Ga-68 DOTATATE) Shows receptor-positive tumour and spread
FDG PET-CT More useful for higher-grade tumours

Under the microscope

Feature Description
Pattern Nests, ribbons and rosettes of uniform cells
Neuroendocrine markers Synaptophysin, chromogranin A, INSM1 positive
Mitotic count and necrosis Separate typical from atypical carcinoid
Ki-67 index Indicates growth rate
Hormone stains ACTH staining in tumours causing Cushing’s syndrome

5. Symptoms

Some patients have no symptoms, and the tumour is found on a chest scan done for another reason.

Common symptoms

  • Chest pain or pressure
  • Cough
  • Shortness of breath

Less common symptoms

Symptom Possible cause
Weight gain in the face and trunk, thin skin, high blood pressure, high blood sugar, muscle weakness Cushing’s syndrome from ACTH production
Swelling of the face, neck and arms Pressure on the superior vena cava
Hoarse voice Pressure on the nerve to the voice box
Bone pain Spread to bone
Flushing and diarrhoea Carcinoid syndrome (rare)
Kidney stones, bone thinning High calcium from parathyroid disease in MEN1

When to seek medical advice

See a doctor for persistent chest pain, cough or breathlessness, or for features of Cushing’s syndrome such as rapid weight gain, purple stretch marks and easy bruising. People with MEN1 should attend their planned surveillance scans.

6. Diagnosis

Test Purpose
CT of the chest Size and extent of the tumour
Somatostatin receptor PET-CT Staging and checking receptor status for treatment
Biopsy CT-guided needle or surgical biopsy, when the diagnosis is uncertain
Blood tests: chromogranin A, cortisol, ACTH Detect hormone production
Calcium, parathyroid hormone, pituitary tests Screen for MEN1
Genetic testing for MEN1 Especially in younger patients or with a family history
Lung function tests Before surgery

Staging

There is no staging system designed specifically for thymic NETs. Doctors use the TNM system for thymic tumours or the Masaoka-Koga system. A specific staging system has been called for (Gaur, Leary and Yao, 2010).

Stage group General meaning
Localised Confined to the thymus and its capsule
Locally advanced Invades nearby fat, pleura, pericardium, lung or vessels
Nodal spread Involves chest lymph nodes
Distant spread Bone, liver, lung or other organs

7. Treatment

Treatment is planned by a multidisciplinary team with experience in thoracic surgery and neuroendocrine tumours. European guidance on lung and thymic carcinoids provides practical recommendations for diagnosis, treatment and follow-up (Baudin et al., 2026).

Surgery

Aspect Details
Aim Complete removal of the tumour and the whole thymus
Approach Usually through the breastbone (sternotomy); minimally invasive surgery for small tumours
Extended resection Parts of the lung, pericardium or vessels may be removed
Lymph nodes Sampling or removal is recommended
Effect on survival Surgery is linked with better survival in database studies

In SEER data, surgery was associated with better survival, while radiotherapy as part of primary treatment showed no clear benefit (Gaur, Leary and Yao, 2010).

Radiotherapy

Situation Role
Positive margins Linked with improved survival in national data (Bakhos et al., 2020)
Locally advanced tumours Considered after surgery
Tumours that cannot be removed Combined with drug treatment
Painful bone spread Symptom relief

Drug treatments for advanced disease

Treatment Notes
Somatostatin analogues (octreotide, lanreotide) Slow growth of receptor-positive tumours; control hormone symptoms
Everolimus Targeted tablet for progressive carcinoids
Peptide receptor radionuclide therapy (PRRT) Radioactive treatment for receptor-positive tumours
Chemotherapy Temozolomide-based or platinum-etoposide regimens, especially for higher grades
Clinical trials Encouraged for advanced disease (Lausi et al., 2014)

Treating Cushing’s syndrome

Treatment Purpose
Removing the tumour The most effective way to cure the hormone excess
Cortisol-lowering medicines Control symptoms before surgery or if the tumour cannot be removed
Adrenal gland removal A last resort for uncontrolled Cushing’s syndrome

Recovery after thymic surgery

Period What to expect
Hospital stay Usually 3-7 days after sternotomy; shorter after keyhole surgery
First 6 weeks Breastbone healing; avoid heavy lifting and driving
6-12 weeks Gradual return to normal activities and work
Longer term Breathing and fitness continue to improve with exercise

Side effects

Treatment Possible side effects
Sternotomy Chest pain, slow bone healing, breathing problems, infection
Radiotherapy Tiredness, sore swallowing, lung or heart inflammation
Somatostatin analogues Loose stools, abdominal discomfort, gallstones
Everolimus Mouth ulcers, rash, lung inflammation, high blood sugar
PRRT Nausea, low blood counts, kidney effects
Chemotherapy Tiredness, infection risk, nausea

8. Outlook (prognosis)

Factor Effect
Stage Advanced stage is linked with poorer survival
Grade Higher grade is linked with poorer survival
Tumour size Larger tumours do worse
Complete surgical removal Better survival
Age and other illnesses Affect survival

In a national database of nearly 1,500 patients with thymic NETs or thymic carcinoma, five-year survival was 62% for thymic NETs (Bakhos et al., 2020). Stage, grade, surgical removal and tumour size were all linked with survival in SEER data (Gaur, Leary and Yao, 2010).

Recurrence is common and can occur many years after surgery, so long-term follow-up is needed.

9. Follow-up

Time Typical checks
First 2 years CT every 6 months
Years 3-5 CT every 6-12 months
After 5 years Yearly imaging, often for 10 years or longer
Somatostatin receptor PET If recurrence is suspected
Hormone tests If Cushing’s syndrome was present
MEN1 surveillance Lifelong, for patients with MEN1

10. Living with a thymic neuroendocrine tumour

  • Keep follow-up scans, even many years after treatment
  • Tell relatives about MEN1 if you have it, so they can be offered testing
  • Stop smoking to protect your lungs and heart, especially after chest surgery
  • Report new symptoms, such as chest pain, weight change or bone pain
  • Rebuild fitness gradually after chest surgery, with physiotherapy if offered
  • Seek support from neuroendocrine tumour charities and patient groups

11. Frequently asked questions

Question Answer
Is a thymic carcinoid the same as thymoma? No; it comes from different cells and is treated differently
Is it benign because it is called a carcinoid? No; thymic carcinoids are cancers and can spread
Why test for MEN1? Some thymic carcinoids are part of this inherited condition
Can it cause hormone problems? Yes, most often Cushing’s syndrome
Will I need chemotherapy? Not usually after complete removal; it is used for advanced or high-grade disease
Can it come back? Yes, sometimes years later
Is it inherited? Usually not, but a minority of patients have MEN1, which can run in families
Can I return to work? Most people can, typically a few months after surgery
What is a somatostatin receptor scan? A PET scan using a tracer that sticks to receptors on many NET cells

12. Questions to ask your care team

  • Is my tumour a typical or atypical carcinoid, or a high-grade carcinoma?
  • Should I be tested for MEN1?
  • Is the tumour producing hormones?
  • Can it be completely removed?
  • Will I need radiotherapy or drug treatment?
  • Does my tumour show up on a somatostatin receptor scan?
  • How long will follow-up continue?

Resources

  1. Bakhos, C.T. et al. (2020) ‘Thymic neuroendocrine tumors and thymic carcinoma: demographics, treatment, and survival’, Innovations (Philadelphia), 15(5), pp. 468-474.
  2. Baudin, E. et al. (2026) ‘European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids’, Journal of Neuroendocrinology, 38(4), e70174.
  3. De Jong, M.C. and Parameswaran, R. (2022) ‘Revisiting the evidence for routine transcervical thymectomy for the prevention of thymic carcinoid tumours in MEN-1 patients’, Oncology, 100(12), pp. 696-700.
  4. Gaur, P., Leary, C. and Yao, J.C. (2010) ‘Thymic neuroendocrine tumors: a SEER database analysis of 160 patients’, Annals of Surgery, 251(6), pp. 1117-1121.
  5. Lausi, P.O. et al. (2014) ‘Thymic neuroendocrine tumors’, Thoracic Surgery Clinics, 24(3), pp. 327-332.
  6. National Cancer Institute (2026) Thymoma and Thymic Carcinoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/thymus-cancer/hp/thymoma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.